Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 – 2014)

Bibliography

• Moore JP, McKeating JA, Norton WA, et al. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J Virol 1991;65:1133-40
   PubMed Web of Science ®Google Scholar
• Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-15
   PubMed Web of Science ®Google Scholar
• Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73
   PubMed Web of Science ®Google Scholar
• Weissenhorn W, Dessen A, Harrison SC, et al. Atomic Structure of the Ectodomain from HIV-1 gp41. Nature 1997;387:426-8
   PubMed Web of Science ®Google Scholar
• Lu M, Kim PS. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997;15:465-71
   PubMed Web of Science ®Google Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4
   PubMed Web of Science ®Google Scholar
• New York Blood Center. Synthetic peptides as inhibitors of HIV-1. US5444044; 1992
   Google Scholar
• Jiang S, Lin K, Strick N, et al. HIV-1 inhibition by a peptide. Nature 1993;365:113
   PubMed Web of Science ®Google Scholar
• Jiang S, Lin K, Strick N, et al. Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem Biophys Res Commun 1993;195:533-8
   PubMed Web of Science ®Google Scholar
• Duke University. Synthetic peptide inhibitors of HIV transmission. US5464933; 1993
   Google Scholar
• Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3
   PubMed Web of Science ®Google Scholar
• Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91:9770-4
   PubMed Web of Science ®Google Scholar
• Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-82
   PubMedGoogle Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Henry K, O’Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south America. N Engl J Med 2003;348:2175-85
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves Fuzeon. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm 2003
   Google Scholar
• Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93
   PubMed Web of Science ®Google Scholar
• Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-47
   PubMed Web of Science ®Google Scholar
• Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43:60-4
   PubMed Web of Science ®Google Scholar
• Bellows ML, Taylor MS, Cole PA, et al. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys J 2010;99:3445-53
   Google Scholar
• New York Blood Center. Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors. US7919101; 2010
   Google Scholar
• New York Blood Center. Bifunctional molecules for inhibiting HIV entry. US8828931; 2009
   Google Scholar
• New York Blood Center. Bifunctional molecules for inactivating HIV and blocking HIV entry. US8828932; 2011
   Google Scholar
• New York Blood Center. Trimeric HIV fusion inhibitors for treating or preventing HIV infection. US20100204120; 2009
   Google Scholar
• He Y, Xiao Y, Song H, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283:11126-34
   PubMed Web of Science ®Google Scholar
• Delmedico M, Bray B, Cammack N, et al. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties [abstract No. 48]. 13th Conference on Retroviruses and Opportunistic Infections 2006, Denver, Colorado, USA; 5 – 8 February
   Google Scholar
• Dwyer JJ, Wilson KL, Davison DK, et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007;104:12772-7
   PubMed Web of Science ®Google Scholar
• Pan C, Lu H, Qi Z, et al. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS 2009;23:639-41
   PubMedGoogle Scholar
• Liu S, Lu H, Xu Y, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005;280:11259-73
   PubMed Web of Science ®Google Scholar
• Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-94
   PubMed Web of Science ®Google Scholar
• Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-40
   PubMed Web of Science ®Google Scholar
• Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-19
   PubMed Web of Science ®Google Scholar
• Pan C, Cai L, Lu H, et al. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. J Biol Chem 2011;286:28425-34
   PubMed Web of Science ®Google Scholar
• Dervillez X, Huther A, Schuhmacher J, et al. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. ChemMedChem 2006;1:330-9
   Google Scholar
• Lu L, Pan C, Li Y, et al. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology 2012;9:104
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
   PubMed Web of Science ®Google Scholar
• Louis JM, Nesheiwat I, Chang L, et al. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003;278:20278-85
   PubMed Web of Science ®Google Scholar
• Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001;98:11187-92
   PubMed Web of Science ®Google Scholar
• Eckert DM, Malashkevich VN, Hong LH, et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999;99:103-15
   PubMed Web of Science ®Google Scholar
• Yang X, Lee J, Mahony EM, et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76:4634-42
   PubMed Web of Science ®Google Scholar
• Papanikolopoulou K, Forge V, Goeltz P, et al. Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage T4 fibritin. J Biol Chem 2004;279:8991-8
   PubMed Web of Science ®Google Scholar
• Chen X, Lu L, Qi Z, et al. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J Biol Chem 2010;285:25506-15
   Google Scholar
• Lazzarin A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother 2005;6:453-64
   PubMed Web of Science ®Google Scholar
• Trimeris, Inc. Conjugates comprised of polymer and HIV gp41-derived peptides and their use in therapy. US0016225; 2010
   Google Scholar
• Tianjin FusoGen Pharmaceuticals, Inc. Use of antiviral peptides for treatment of infection caused by drug-resistant HIV. US20100021427; 2009
   Google Scholar
• Tianjin FusoGen Pharmaceuticals, Inc. Drug composition for preventing or treating HIV infection and application thereof. CN102247590; 2010
   Google Scholar
• Yao X, Chong H, Zhang C, et al. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem 2012;287:6788-96
   PubMed Web of Science ®Google Scholar
• Franquelim HG, Veiga AS, Weissmnller G, et al. Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor sifuvirtide towards phosphatidylcholine-rich rigid membranes. Biochim Biophys Acta BBABiomembr 2010;1798:1234-43
   Google Scholar
• Frontier Biotechnologies Co. Ltd. Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties. US8470527; 2009
   Google Scholar
• Xie D, Yao C, Wang L, et al. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 2010;54:191-6
   PubMed Web of Science ®Google Scholar
• Chong H, Yao X, Zhang C, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 2012;7:e32599
   PubMed Web of Science ®Google Scholar
• Institute of Pathogen Biology Chinese Academy of Medical Science. Short polypeptide inhibiting HIV and pharmacal use. WO2014022947; 2012
   Google Scholar
• He Y, Chen J, Li J, et al. Identification of a critical motif for the HIV-1 gp41 core structure: implication for designing novel anti-HIV fusion inhibitors. J Virol 2008;82:6349-58
   Google Scholar
• He Y, Cheng J, Lu H, et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA 2008;105:16332-7
   PubMed Web of Science ®Google Scholar
• Chong H, Yao X, Qiu Z, et al. Structural insight of HIV-1 fusion inhibitor CP621-652 discovers the critical residues for viral entry and inhibition. J Biol Chem 2012;287:20281-9
   Google Scholar
• Chong H, Yao X, Sun J, et al. The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J Biol Chem 2012;287:34558-68
   PubMed Web of Science ®Google Scholar
• Chong H, Yao X, Qiu Z, et al. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J 2013;27:1203-13
   Google Scholar
• Chong H, Yao X, Qiu Z, et al. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother 2014;69:2759-69
   PubMed Web of Science ®Google Scholar
• Chong H, Qiu Z, Sun J, et al. Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK. Retrovirology 2014;11:40
   Google Scholar
• Institute of Pathogen Biology Chinese Academy of Medical Science. Cholesterol modified anti-HIV polypeptide medicament and application thereof. CN102180951; 2011
   Google Scholar
• Ingallinella P, Bianchi E, Ladwa NA, et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA 2009;106:5801-6
   Web of Science ®Google Scholar
• Hovanessian AG, Briand JP, Said EA, et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 2004;21:617-27
   Google Scholar
• Murata M, Peranen J, Schreiner R, et al. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA 1995;92:10339-43
   PubMed Web of Science ®Google Scholar
• Huang JH, Lu L, Lu H, et al. Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. J Biol Chem 2007;282:6143-52
   Google Scholar
• Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P. L. A. China CN. Artificially designed anti-HIV infection polypeptide, composition and use. WO2013075594; 2012
   Google Scholar
• Qi Z, Shi W, Xue N, et al. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem 2008;283:30376-84
   Google Scholar
• Shi W, Qi Z, Pan C, et al. Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs. Biochem Biophys Res Commun 2008;374:767-72
   Google Scholar
• Shi W, Cai L, Lu L, et al. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. Chem Commun (Camb) 2012;48:11579-81
   Google Scholar
• Brauer F, Schmidt K, Zahn RC, et al. A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob Agents Chemother 2013;57:679-88
   Google Scholar
• Yeda Research and Development Co. Ltd. Lipopeptide inhibitors of HIV-1. US20120028887; 2011
   Google Scholar
• Wexler-Cohen Y, Shai Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J 2007;21:3677-84
   Google Scholar
• Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998;95:15613-17
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Viard M, Unger L, et al. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. FASEB J 2012;26:4628-36
   Web of Science ®Google Scholar
• The Regents of the University of California. Potent HIV inhibitors targeting CCR5 and gp41. WO109314; 2012
   Google Scholar
• Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000;53:274-8
   PubMed Web of Science ®Google Scholar
• Ernst JT, Kutzki O, Debnath AK, et al. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl 2002;41:278-81
   PubMed Web of Science ®Google Scholar
• Jiang S, Lu H, Liu S, et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 2004;48:4349-59
   PubMed Web of Science ®Google Scholar
• Katritzky AR, Tala SR, Lu H, et al. Design, synthesis, and structure-activity relationship of a novel series of 2-Aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidin-ylidenemethyl)furans as HIV-1 entry inhibitors. J Med Chem 2009;52:7631-9
   PubMed Web of Science ®Google Scholar
• Jiang S, Tala SR, Lu H, et al. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thi azolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. J Med Chem 2011;54:572-9
   Google Scholar